Proteomic approaches for cancer epigenetics research

References

• Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284–299.
   PubMed Web of Science ®Google Scholar
• Shen L, Shi Q, Wang W. Double agents: genes with both oncogenic and tumor-suppressor functions. Oncogenesis. 2018;7:25.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799.
   PubMed Web of Science ®Google Scholar
• Landau DA, Clement K, Ziller MJ, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014;26:813–825.
   PubMed Web of Science ®Google Scholar
• You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22:9–20.
   PubMed Web of Science ®Google Scholar
• Huang H, Sabari BR, Garcia BA, et al. SnapShot: histone modifications. Cell. 2014;159:458–458.e1.
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–45.
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–1080.
   PubMed Web of Science ®Google Scholar
• Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407–412.
   PubMed Web of Science ®Google Scholar
• Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823–837.
   PubMed Web of Science ®Google Scholar
• Lehnertz B, Ueda Y, Derijck AAHA, et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol. 2003;13:1192–1200.
   PubMed Web of Science ®Google Scholar
• Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science. 2004;306:1574–1577.
   PubMed Web of Science ®Google Scholar
• Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107:21931–21936.
   PubMed Web of Science ®Google Scholar
• Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146:1016–1028.
   PubMed Web of Science ®Google Scholar
• Dai L, Peng C, Montellier E, et al. Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. Nat Chem Biol. 2014;10:365–370.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang D, Wang Y, et al. Lysine benzoylation is a histone mark regulated by SIRT2. Nat Commun. 2018;9:3374.
   PubMed Web of Science ®Google Scholar
• Sidoli S, Schwämmle V, Ruminowicz C, et al. Middle-down hybrid chromatography/tandem mass spectrometry workflow for characterization of combinatorial post-translational modifications in histones. Proteomics. 2014;14:2200–2211.
   PubMed Web of Science ®Google Scholar
• Schwämmle V, Sidoli S, Ruminowicz C, et al. Systems level analysis of histone H3 post-translational modifications (PTMs) reveals features of PTM crosstalk in chromatin regulation. Mol Cell Proteomics. 2016;15:2715–2729.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Fornelli L, Compton PD, et al. Unabridged analysis of human histone H3 by differential top-down mass spectrometry reveals hypermethylated proteoforms from MMSET/NSD2 overexpression. Mol Cell Proteomics. 2016;15:776–790.
   PubMed Web of Science ®Google Scholar
• Wang T, Holt MV, Young NL. Early butyrate induced acetylation of histone H4 is proteoform specific and linked to methylation state. Epigenetics. 2018;13(5):519–535. doi: 10.1080/15592294.2018.1475979.
   Web of Science ®Google Scholar
• Cristobal A, Marino F, Post H, et al. Toward an optimized workflow for middle-down proteomics. Anal Chem. 2017;89:3318–3325.
   PubMed Web of Science ®Google Scholar
• Sidoli S, Garcia BA. Middle-down proteomics: a still unexploited resource for chromatin biology. Expert Rev Proteomics. 2017;14:617–626.
   PubMed Web of Science ®Google Scholar
• Sidoli S, Vandamme J, Salcini AE, et al. Dynamic changes of histone H3 marks during Caenorhabditis elegans lifecycle revealed by middle-down proteomics. Proteomics. 2016;16:459–464.
   PubMed Web of Science ®Google Scholar
• Schräder CU, Ziemianowicz DS, Merx K, et al. Simultaneous proteoform analysis of histones H3 and H4 with a simplified middle-down proteomics method. Anal Chem. 2018;90:3083–3090.
   PubMed Web of Science ®Google Scholar
• Catherman AD, Skinner OS, Kelleher NL. Top down proteomics: facts and perspectives. Biochem Biophys Res Commun. 2014;445:683–693.
   PubMed Web of Science ®Google Scholar
• Dunham WH, Mullin M, Gingras A-C. Affinity-purification coupled to mass spectrometry: basic principles and strategies. Proteomics. 2012;12:1576–1590.
   PubMed Web of Science ®Google Scholar
• Yates JR 3rd. The revolution and evolution of shotgun proteomics for large-scale proteome analysis. J Am Chem Soc. 2013;135:1629–1640.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537:347–355.
   PubMed Web of Science ®Google Scholar
• Huang H, Lin S, Garcia BA, et al. Quantitative proteomic analysis of histone modifications. Chem Rev. 2015;115:2376–2418.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Huang X, Kelleher NL. Epiproteomics: quantitative analysis of histone marks and codes by mass spectrometry. Curr Opin Chem Biol. 2016;33:142–150.
   PubMed Web of Science ®Google Scholar
• Janssen KA, Sidoli S, Garcia BA. Recent achievements in characterizing the histone code and approaches to integrating epigenomics and systems biology. Methods Enzymol. 2017;586:359–378.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. [Internet]. 2017;357:eaal2380.
   PubMed Web of Science ®Google Scholar
• Stedman E, Stedman E. Cell specificity of histones. Nature. 1950;166:780–781.
   PubMed Web of Science ®Google Scholar
• Cruft HJ, Mauritzen CM, Stedman E. Abnormal properties of histones from malignant cells. Nature. 1954;174:580–585.
   PubMed Web of Science ®Google Scholar
• Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;51:786–794.
   PubMed Web of Science ®Google Scholar
• Roth JS. Histones in development, growth and cancer. Nature. 1965;207:599–601.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Moretti S, Minucci S, et al. SILAC-based proteomic analysis to dissect the “histone modification signature” of human breast cancer cells. Amino Acids. 2011;41:387–399.
   PubMed Web of Science ®Google Scholar
• Leroy G, Dimaggio PA, Chan EY, et al. A quantitative atlas of histone modification signatures from human cancer cells. Epigenetics Chromatin. 2013;6:20.
   PubMed Web of Science ®Google Scholar
• Hü K, Konze KD, Jin J. Selective inhibitors of protein methyltransferases. J Med Chem. 2015;58:1596–1629.
   PubMed Web of Science ®Google Scholar
• Barsyte-Lovejoy D, Li F, Oudhoff MJ, et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014;111:12853–12858.
   PubMed Web of Science ®Google Scholar
• Cao F, Townsend EC, Karatas H, et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 2014;53:247–261.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Li F, Babault N, et al. Discovery of potent and selective inhibitors for G9a-Like Protein (GLP) lysine methyltransferase. J Med Chem. 2017;60:1876–1891.
   PubMedGoogle Scholar
• Kuntz KW, Campbell JE, Keilhack H, et al. The importance of being me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat. J Med Chem. 2016;59:1556–1564.
   PubMed Web of Science ®Google Scholar
• Italiano A, Soria J-C, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19:649–659.
   PubMed Web of Science ®Google Scholar
• Verma SK, Tian X, LaFrance LV, et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett. 2012;3:1091–1096.
   PubMed Web of Science ®Google Scholar
• Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8:1324–1334.
   PubMed Web of Science ®Google Scholar
• Zheng W, Ibáñez G, Wu H, et al. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc. 2012;134:18004–18014.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122:1017–1025.
   PubMed Web of Science ®Google Scholar
• Ma A, Yu W, Li F, et al. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J Med Chem. 2014;57:6822–6833.
   PubMedGoogle Scholar
• Bromberg KD, Mitchell TRH, Upadhyay AK, et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017;13:317–324.
   PubMed Web of Science ®Google Scholar
• Noberini R, Osti D, Miccolo C, et al. Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Res. 2018;46:3817–3832.
   PubMed Web of Science ®Google Scholar
• Noberini R, Uggetti A, Pruneri G, et al. Pathology tissue-quantitative mass spectrometry analysis to profile histone post-translational modification patterns in patient samples. Mol Cell Proteomics. 2016;15:866–877.
   PubMed Web of Science ®Google Scholar
• Noberini R, Longuespée R, Richichi C, et al. PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. Clin Clin Epigenet. 2017;9:69.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025–3034.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520–1529.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, Kee HJ, Choe N-W, et al. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol. 2008;28:2023–2034.
   PubMed Web of Science ®Google Scholar
• Marango J, Shimoyama M, Nishio H, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111:3145–3154.
   PubMed Web of Science ®Google Scholar
• Li Y, Trojer P, Xu C-F, et al. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem. 2009;284:34283–34295.
   PubMed Web of Science ®Google Scholar
• Nimura K, Ura K, Shiratori H, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009;460:287–291.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia E, Popovic R, Min D-J, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117:211–220.
   PubMed Web of Science ®Google Scholar
• Pei H, Zhang L, Luo K, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011;470:124–128.
   PubMed Web of Science ®Google Scholar
• Kuo AJ, Cheung P, Chen K, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011;44:609–620.
   PubMed Web of Science ®Google Scholar
• Michishita E, Park JY, Burneskis JM, et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16:4623–4635.
   PubMed Web of Science ®Google Scholar
• Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487:114–118.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897–903.
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–1628.
   PubMed Web of Science ®Google Scholar
• Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol. 2010;28:1358–1365.
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–740.
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–118.
   PubMed Web of Science ®Google Scholar
• Van Aller GS, Reynoird N, Barbash O, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012;7:340–343.
   PubMed Web of Science ®Google Scholar
• Foreman KW, Brown M, Park F, et al. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One. 2011;6:e22290.
   PubMed Web of Science ®Google Scholar
• Mazur PK, Reynoird N, Khatri P, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510:283–287.
   PubMed Web of Science ®Google Scholar
• Yao Y-L, Yang W-M. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. BioMed Res Int. [Internet]. 2010 [cited 2018 Sep 11]. 2011. Available from: https://www.hindawi.com/journals/bmri/2011/146493/
   Google Scholar
• Martínez-Redondo P, Vaquero A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer. 2013;4:148–163.
   PubMedGoogle Scholar
• Weigt D, Hopf C, Médard G. Studying epigenetic complexes and their inhibitors with the proteomics toolbox. Clin Clin Epigenet. 2016;8:76.
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315–326.
   PubMed Web of Science ®Google Scholar
• Voigt P, LeRoy G, Drury WJ 3rd, et al. Asymmetrically modified nucleosomes. Cell. 2012;151:181–193.
   PubMed Web of Science ®Google Scholar
• Schmitges FW, Prusty AB, Faty M, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell. 2011;42:330–341.
   PubMed Web of Science ®Google Scholar
• Yuan W, Xu M, Huang C, et al. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem. 2011;286:7983–7989.
   PubMed Web of Science ®Google Scholar
• Cai L, Rothbart SB, Lu R, et al. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell. 2013;49:571–582.
   PubMed Web of Science ®Google Scholar
• Schwanhäusser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337–342.
   PubMed Web of Science ®Google Scholar
• Taverna SD, Li H, Ruthenburg AJ, et al. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14:1025–1040.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Mulder KW, Denissov S, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007;131:58–69.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Eberl HC, Matarese F, et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell. 2010;142:967–980.
   PubMed Web of Science ®Google Scholar
• Vermeulen M. Identifying chromatin readers using a SILAC-based histone peptide pull-down approach. Methods Enzymol. 2012;512:137–160.
   PubMed Web of Science ®Google Scholar
• Eberl HC, Spruijt CG, Kelstrup CD, et al. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. Mol Cell. 2013;49:368–378.
   PubMed Web of Science ®Google Scholar
• Spruijt CG, Baymaz HI, Vermeulen M. Identifying specific protein–DNA interactions using SILAC-based quantitative proteomics. In: Bina M, editor. Gene regulation: methods and protocols. Totowa, NJ: Humana Press; 2013. p. 137–157.
   Google Scholar
• Makowski MM, Gräwe C, Foster BM, et al. Global profiling of protein-DNA and protein-nucleosome binding affinities using quantitative mass spectrometry. Nat Commun. 2018;9:1653.
   PubMed Web of Science ®Google Scholar
• Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10:1107–1117.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002;10:1119–1128.
   PubMed Web of Science ®Google Scholar
• Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823–833.
   PubMed Web of Science ®Google Scholar
• Meyer C, Schneider B, Jakob S, et al. The MLL recombinome of acute leukemias. Leukemia. 2006;20:777–784.
   PubMed Web of Science ®Google Scholar
• Meyer C, Burmeister T, Gröger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–284.
   PubMed Web of Science ®Google Scholar
• Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011;152:141–154.
   PubMed Web of Science ®Google Scholar
• Yokoyama A. Transcriptional activation by MLL fusion proteins in leukemogenesis. Exp Hematol. 2017;46:21–30.
   PubMed Web of Science ®Google Scholar
• Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol. 1998;18:122–129.
   PubMed Web of Science ®Google Scholar
• Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20:5695–5707.
   PubMed Web of Science ®Google Scholar
• Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110:4445–4454.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Lin M, Naresh A, et al. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell. 2010;17:198–212.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Wang Z, Wysocka J, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol. 2004;24:5639–5649.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008;14:36–46.
   PubMed Web of Science ®Google Scholar
• Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell. 2010;17:609–621.
   PubMed Web of Science ®Google Scholar
• Bach C, Mueller D, Buhl S, et al. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene. 2009;28:815–823.
   PubMed Web of Science ®Google Scholar
• Monroe SC, Jo SY, Sanders DS, et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol. 2011;39:77–86.e1–e5.
   PubMed Web of Science ®Google Scholar
• Okuda H, Kanai A, Ito S, et al. AF4 uses the SL1 components of RNAP1 machinery to initiate MLL fusion- and AEP-dependent transcription. Nat Commun. 2015;6:8869.
   PubMed Web of Science ®Google Scholar
• Okuda H, Stanojevic B, Kanai A, et al. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J Clin Invest. 2017;127:1918–1931.
   PubMed Web of Science ®Google Scholar
• Skucha A, Ebner J, Schmöllerl J, et al. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun. 2018;9:1983.
   PubMed Web of Science ®Google Scholar
• Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6:429–439.
   PubMed Web of Science ®Google Scholar
• Mohamed AA, Tan S-H, Mikhalkevich N, et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer. 2010;1:197–208.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648.
   PubMed Web of Science ®Google Scholar
• Hägglöf C, Hammarsten P, Strömvall K, et al. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One. 2014;9:e86824.
   PubMed Web of Science ®Google Scholar
• Sandoval GJ, Pulice JL, Pakula H, et al. Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol Cell. 2018;71:554–566.e7.
   PubMed Web of Science ®Google Scholar
• Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv. 2015;1:e1500447.
   PubMed Web of Science ®Google Scholar
• Wojcik J, Cooper K. Epigenetic alterations in bone and soft tissue tumors. Adv Anat Pathol. 2017;24:362–371.
   PubMed Web of Science ®Google Scholar
• Shen C, Vakoc CR. Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol. 2015;27:57–63.
   PubMed Web of Science ®Google Scholar
• Banito A, Li X, Laporte AN, et al. The SS18-SSX oncoprotein Hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33:527–541.e8.
   PubMed Web of Science ®Google Scholar
• French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304–307.
   PubMed Web of Science ®Google Scholar
• French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27:2237–2242.
   PubMed Web of Science ®Google Scholar
• Gebre-Medhin S, Nord KH, Möller E, et al. Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors. Am J Pathol. 2012;181:1069–1077.
   PubMed Web of Science ®Google Scholar
• Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A. 2001;98:6348–6353.
   PubMed Web of Science ®Google Scholar
• Kao Y-C, Sung Y-S, Zhang L, et al. Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with clear cell sarcoma of kidney. Am J Surg Pathol. 2016;40:1009–1020.
   PubMed Web of Science ®Google Scholar
• Karlsson J, Valind A, Gisselsson D. BCOR internal tandem duplication and YWHAE-NUTM2B/E fusion are mutually exclusive events in clear cell sarcoma of the kidney. Genes Chromosomes Cancer. 2016;55:120–123.
   PubMed Web of Science ®Google Scholar
• Jde DR, van Den Heuvel-Eibrink MM, Kollen WJW, et al. Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion. Genes Chromosomes Cancer. 2016;55:237–241.
   PubMed Web of Science ®Google Scholar
• Myers SA, Wright J, Peckner R, et al. Discovery of proteins associated with a predefined genomic locus via dCas9-APEX-mediated proximity labeling. Nat Methods. [Internet]. 2018. DOI:10.1038/s41592-018-0007-1
   Web of Science ®Google Scholar
• Weinberg DN, Allis CD, Lu C. Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb Perspect Med. [Internet]. 2017;7:a026443.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu X-Y, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226–231.
   PubMed Web of Science ®Google Scholar
• Wu G, Broniscer A, Mc Eachron TA, et al. Somatic histone H3 alterations in paediatric diffuse intrinsic pontine gliomas and non‐ brainstem glioblastomas. Nat Genet. 2012.
   Web of Science ®Google Scholar
• Pajtler KW, Wen J, Sill M, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol. 2018;136:211–226.
   PubMed Web of Science ®Google Scholar
• Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–1482.
   PubMed Web of Science ®Google Scholar
• Joseph CG, Hwang H, Jiao Y, et al. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014;53:15–24.
   PubMed Web of Science ®Google Scholar
• Sarungbam J, Agaram N, Hwang S, et al. Symplastic/pseudoanaplastic giant cell tumor of the bone. Skeletal Radiol. 2016;45:929–935.
   PubMed Web of Science ®Google Scholar
• Papillon-Cavanagh S, Lu C, Gayden T, et al. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet. 2017;49:180–185.
   PubMed Web of Science ®Google Scholar
• Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340:857–861.
   PubMed Web of Science ®Google Scholar
• Chan K-M, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013;27:985–990.
   PubMed Web of Science ®Google Scholar
• Fang D, Gan H, Lee J-H, et al. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science. 2016;352:1344–1348.
   PubMed Web of Science ®Google Scholar
• Shi L, Shi J, Shi X, et al. Histone H3.3 G34 mutations alter histone H3K36 and H3K27 methylation in Cis. J Mol Biol. 2018;430:1562–1565.
   PubMed Web of Science ®Google Scholar
• Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017;23:483–492.
   PubMed Web of Science ®Google Scholar
• Lewis PW, Allis CD. Poisoning the “histone code” in pediatric gliomagenesis. Cell Cycle. 2013;12:3241–3242.
   PubMed Web of Science ®Google Scholar
• Dann GP, Liszczak GP, Bagert JD, et al. ISWI chromatin remodellers sense nucleosome modifications to determine substrate preference. Nature. 2017;548:607–611.
   PubMed Web of Science ®Google Scholar